DURHAM, North Carolina, February 3, 2022 /PRNewswire/ — February 3, 2022a collaboration agreement was signed between Allosteric Biosciencea company founded in 2021 integrating quantum computing and artificial intelligence with biomedical sciences to create improved treatments for aging and longevity and Polaris Quantum Biotech, a company at the forefront of quantum computing for drug discovery. Together, they use advances in quantum computing and artificial intelligence for the development of new pharmaceutical products.
Improving aging, longevity and age-related diseases is a flagship program of Allosteric Bioscience and purpose of this agreement, supported by an investment in Polarisqb. This joint program uses quantum computing (QC) and artificial intelligence (AI) to create an inhibitor of a key protein involved in aging that could have health benefits representing a multi-billion dollar market. Allosteric Bioscience uses its “QAB” platform to integrate QC, AI, genetics, genomics, systems biology, epigenetics and proteomics, as well as two aging platforms: “ALT” – Aging Longevity Targets and “ALM – Aging Longevity Modulators.
dr. Chahar KeinanPolaris CEOqb said, “Quantum computing technology is maturing, allowing us to revolutionize drug discovery timelines, while improving the overall profile of engineered drugs.qbof the Tachyon platform. The application of quantum computers to solving these complex questions is extraordinary.”
dr. Arthur P. BollonPresident of Allosteric Bioscience said: “The agreement between Allosteric Bioscience and Polarisqb represents an important step in the implementation of the allosteric bioscience strategy of integrating quantum computing and advanced AI with biomedical sciences for the creation and development of advanced treatments for the improvement of aging, longevity and age-related diseases.
Polaris Quantum Biotech, a leader in quantum computing for drug discovery, has created the first quantum computer-based drug discovery platform. Founded in 2020 by Chahar KeinanCEO and Bill ShipmanCTO, Polarisqb uses the cloud, quantum computing and machine learning to process, evaluate and identify lead molecules 10,000 times faster than alternative solutions. These high-quality drug leads are synthesized, tested, and licensed to development partners in months, rather than years. Information is available at www.Polarisqb.com
Allosteric Bioscience founders, Bruce Meyer, Arthur P. Bollondoctorate and Pierre SordilloPh.D., MD, have decades of expertise in the biotechnology industry as well as biomedical disciplines including genomics, epigenetics, systems biology, proteomics as well as oncology and physics quantum. Bruce Meyer and Dr. Bollon, founded several biotechnology companies, including Cytoclonal Pharmaceuticals (Dr. Bollon served as Chairman and CEO) which merged to create OPKO Health, a NASDAQ company with a market capitalization of $2 billion. Dr. Sordillo, who has a background in quantum information theory, is a leader in the treatment of sarcomas and other cancers and has managed more than 50 clinical trials at leading institutions including the Sloan Kettering Cancer Centre.
For more information on allosteric bioscience: Dr. Arthur P. Bollon– [email protected] Where Bruce Meyer– [email protected]
For more information on Polarisqb: dr. Chahar Keinan – [email protected] Where will simpson – [email protected].
SOURCE PolarisQB